The FDA Modernization Act 3.0 aims to update regulations regarding nonclinical testing methods used in the development of drugs and medical products. The primary objective is to replace outdated references to animal testing with broader nonclinical testing methods, which may include alternative approaches that do not rely on animal subjects. One of the key provisions of this act is that the Secretary of Health and Human Services, through the Commissioner of Food and Drugs, must publish an interim final rule within one year of the act's enactment.